Enanta Pharmaceuticals Inc (ENTA) · Oct 29, 2026 · Other events
Patent invalidated — UPC ruled EP 4 051 265 invalid
Enanta’s patent ruling invalidates its European Paxlovid claim, closing another potential path to Pfizer damages as RSV becomes its core growth focus.
Enanta is a clinical-stage biotech increasingly centered on its RSV pipeline, while royalty revenue from AbbVie’s hepatitis C franchise helps fund development; management recently said its resources could support existing programs into fiscal 2029.
The European Paxlovid claim is now gone. The Unified Patent Court ruled that Enanta’s ’265 patent was invalid and dismissed the related infringement action. 〔0〕 〔1〕
This is adverse, but not a fresh strategic shock. The ruling follows the June 2026 Federal Circuit decision upholding invalidity of Enanta’s corresponding U.S. Paxlovid patent, so the direction of the European case was partly foreshadowed. The new information is that the loss now extends to the 18 EU member states participating in the UPC, eliminating this avenue for potential Pfizer damages across that region.
The core operating story is largely unchanged. The decision does not affect Enanta’s RSV drug development or its existing HCV royalty stream; it removes a possible legal upside rather than disrupting the programs currently driving the company forward.
Bottom line: Enanta loses another route to Paxlovid-related damages, confirming that the litigation is no longer a meaningful source of potential upside. The business remains primarily a funding-and-development story around RSV, not this patent case.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!